PRKAR1A codes for the type 1a regulatory subunit (RIa) of the cAMP-dependent protein kinase A (PKA), an enzyme with an important role in cell cycle regulation and proliferation. PKA dysregulation has been found in various tumors, and PRKAR1A-inactivating mutations have been reported in mostly endocrine neoplasias. In this study, we investigated PKA activity and the PRKAR1A gene in normal and tumor endometrium. Specimens were collected from 31 patients with endometrial cancer. We used as controls 41 samples of endometrium that were collected from surrounding normal tissues or from women undergoing gynecological operations for other reasons. In all samples, we sequenced the PRKAR1A-coding sequence and studied PKA subunit expression; we also determined PKA activity and cAMP binding. PRKAR1A mutations were not found. However, PKA regulatory subunit protein levels, both RIa and those of regulatory subunit type 2b (RIIb), were lower in tumor samples; cAMP binding was also lower in tumors compared with normal endometrium (P!0.01). Free PKA activity was higher in tumor samples compared with that of control tissue (P!0.01). There are significant PKA enzymatic abnormalities in tumors of the endometrium compared with surrounding normal tissue; as these were not due to PRKAR1A mutations, other mechanisms affecting PKA function ought to be explored.
Introduction
Protein kinase A (PKA), a serine-threonine kinase and the main effector of cAMP signaling in most cells, is widely involved in the regulation of cell growth and proliferation (Robinson-White et al. 2006a,b) . PKA holoenzyme is a tetramer composed of two regulatory (R) and two catalytic (C) subunits. Each of the four regulatory subunits (RIa, RIb, RIIa, and RIIb) serves as a binding scaffold for the enzymatically active catalytic subunits and thus the PKA holoenzyme is inactive. Upon binding of the cAMP to the R subunits, the C subunits are released to mediate kinase activity (Meoli et al. 2008) . The most important regulator of PKA activity is its regulatory subunit type 1a (RIa). Mutations of the PRKAR1A gene coding for R1a cause Carney complex (CNC), a multiple neoplasia syndrome associated with skin, heart, and other myxomas, a variety of other tumors, mostly in endocrine tissues, such as the adrenal, thyroid, and pituitary glands, and a number of skin lesions from common nevi and lentigines to blue nevi and caféau-lait spots (Kirschner et al. 2000) . Ovarian and other gonadal tumors also occur in CNC, and changes in R1a protein expression and/or PRKAR1A mutations have been detected in a variety of sporadic (not associated with CNC or any other familial tumor syndrome) lesions (McDaid et al. 1999 , Sandrini et al. 2002 , Bertherat et al. 2003 .
Endometrial cancer is a hormone-dependent lesion. Although there have been no studies to date on PKA, PRKAR1A, or any related molecule in endometrial tumors, several of the hormones that regulate 2003 , Bulun & Simpson 2008 . The aim of this study was to investigate any possible PKA or cAMP signaling aberrations in endometrial cancer. As PRKAR1A is the only PKA-associated gene that has been found mutated in sporadic tumors, we also investigated this gene's coding sequence for any mutations.
Materials and methods

Samples
Thirty-one female patients, 27-81 years old (mean age 60.1 years), diagnosed with endometrial cancer were included in this study. All patients were treated in the First Department of Obstetrics and Gynecology, Athens University Medical School, Alexandra Hospital, Athens, Greece, between 2006 and 2007. In 27 of the 81 patients, tissue from the surrounding endometrium was available; these samples were histologically normal. Normal endometrial tissue was also collected from 14 additional patients who underwent hysterectomy for nononcological indications. These patients had no other cancer diagnoses and their family history was also free of endometrial cancer. None of the patients or the controls had clinical features of CNC (Stratakis et al. 1998 , Sandrini et al. 2002 . All studies were approved by the institutional ethics review board of Alexandra Hospital.
DNA analysis
Tissues were microdissected and DNA was extracted from normal and cancer samples using standard methods (Qiagen DNeasy blood and tissue kit; Qiagen, Inc.). Direct bidirectional sequencing was used to analyze all PRKAR1A-coding sequence (exons 2-10), as previously published (McDaid et al. 1999 , Sandrini et al. 2002 , Bertherat et al. 2003 .
Immunohistochemistry and immunoblotting
Formalin-fixed, paraffin-embedded tumor and normal endometrium from all patients were incubated with antibodies against the PKA subunits RIa (Abcam, Cambridge, MA, USA), RIIa (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), RIIb, and Ca (BD Biosciences, San Jose, CA, USA), as described previously (McDaid et al. 1999 , Sandrini et al. 2002 , Bertherat et al. 2003 . The same antibodies were used for western blot analysis of PKA subunit expression in frozen tissue extracts. For western blotting, tissue was lysed by homogenization in 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM MgCl 2 , 1% NP40, 0.5% sodium deoxycholate, and Protease Inhibitor Cocktail I (EMD4BBiosciences, Darmstadt, Germany) with subsequent centrifugation at 10 000 g for 10 min at 4 8C. Equal amounts of protein lysate were subjected to SDS-PAGE, transferred to nitrocellulose membranes, and probed with antibodies. Complexes were visualized with the appropriate HRP-conjugated secondary antibody and developed by enhanced chemiluminescence procedure (Santa Cruz Biotechnology). Images captured on film were analyzed using the Image Quant Software and were normalized against the expression of the housekeeping gene GAPDH (Abcam) for quantification of PKA subunit protein expression. We only studied PKA subunits that are known to be expressed in endometrial tissue, such as RIa, RIIb, RIIa, and Ca. Endocrine-Related Cancer (2012) 19 457-462 www.endocrinology-journals.org PKA and cAMP binding assays PKA activity was measured in cell extracts following a protocol previously described (Nesterova et al. 1975) . Basal PKA activity reflects free enzymatic activity without stimulation with cAMP, whereas total PKA activity was measured following the addition of cAMP. All determinations of PKA activity were done at least twice for each sample and an average value was calculated. The Gilman procedure was used in order to measure cAMP binding (Gilman 1970) .
Statistical analysis
Tumors (nZ31) and controls (nZ41) were compared using the t-test; P!0.05 indicated significance in difference for any measured value.
Results
DNA sequencing
No pathogenic PRKAR1A mutations were found in any samples (data not shown). In five controls and in nine tumor samples, we found a previously described polymorphism IVS3-5dupT; in six of the nine samples where normal tissue was available from the same patient, the IVS3-5dupT polymorphism was determined to be present in the germline DNA. In addition, one synonymous polymorphism (c.87GO A/p.Ala29Ala) was found in one tumor sample, also in the germline DNA.
PKA subunit expression and cAMP/PKA function
Immunohistochemical staining and western blotting revealed significant downregulation of RIa and RIIb in tumor tissues compared with normal endometrial tissues (Figs 1, 2 and 3) . This is consistent with other studies showing PKA's involvement in tumor formation, even in the absence of mutations (Bertherat et al. 2003) . PKA assay showed increased cAMP-stimulated activity (activation of PKA by an excess of cAMP) in normal compared with tumor tissues (Fig. 4) . This observation was in agreement with western blotting data (Figs 2 and 3) , which showed an increase in Ca in normal tissue. On the contrary, basal PKA activity (free PKA without cAMP) was higher in tumors (Figs 4 and 5) . This could be the result of downregulation of regulatory subunits in tumor tissues. Accordingly, cAMP binding was significantly lower in tumor compared with normal endometrium (Fig. 6) .
These data suggest that downregulation of the RIa and RIIb proteins leads to decreased cAMP binding and increased basal (cAMP-independent) PKA activity in tumors compared with normal endometrial tissue.
Discussion
Endometrial cancer currently represents the most frequent malignancy of the female reproductive tract. The etiology and progression of these tumors involve hormonal actions, mainly of estradiol and progesterone. These steroid hormones in addition to their many other functions affect PKA signaling in endometrial cells (Murk et al. 2008) . PKA and cAMP signaling have also been implicated in cell cycle programming, differentiation, and even immune regulation of endometrial tissue (Tierney et al. 2003) .
In this study, significant abnormalities of PKA activity and cAMP binding were found in endometrial cancer tissue. These were not associated with PRKAR1A-inactivating gene mutations at the germline or somatic level, indicating that epigenetic, micro-RNAmediated, or other mechanisms may be responsible for the downregulation of the RIa protein that was observed by immunoblotting and immunohistochemistry. These data are similar to what we have already published on thyroid, adrenal, and other cancers where PRKAR1A mutations were not found (McDaid et al. 1999 , Sandrini et al. 2002 , Bertherat et al. 2003 . What is, however, different in this study was that yet another of the PKA R subunits, RIIb, was also downregulated at the protein level in endometrial cancer tissues. Downregulation of these widely expressed molecules that are largely responsible for inhibition of PKA activation in all tissues was most likely responsible for the increase in PKA activity that we detected in endometrial cancers. Interestingly, this increase in PKA activity may not be cAMP dependent: following exposure to cAMP, both normal and cancer tissues responded with an increase in PKA activity as expected. However, the stimulating effect of cAMP was less profound in tumor tissues compared with normal endometrium; following cAMP withdrawal, free PKA activity was again found to be higher in cancers. Overall cancers demonstrated lower cAMP binding than normal tissue. These data suggest that increased PKA activity in endometrial cancer may be (at least in part) cAMP-independent due to the downregulation of the R subunits RIa and RIIb. This is a different mechanism of PKA's involvement in cancer than what has been previously described in PRKAR1A-inactivating mutations leading to RIa haploinsufficiency and increased total PKA activity (Griffin et al. 2004 , Kirschner et al. 2005 , Robinson-White et al. 2006a ,b, Greene et al. 2008 : increased PKA activity in these RIa defects was cAMPdependent and associated with increased expression of other R subunits, including RIIa and RIIb.
In conclusion, although no mutations have been found in the PRKAR1A-coding sequence, the significant aberrations, which were detected in the function and expression of the PKA subunits between the malignant and the normal tissues, underline the implication of the cAMP pathway in human endometrial tumor genesis. analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Endocrine-Related Cancer (2012) 19 457-462 www.endocrinology-journals.org
